Perspective Review

134 Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes
Okuyama, H. (Nagoya); Langsjoen, P.H. (Tyler, Tex.); Ohara, N.; Hashimoto, Y. (Nagoya); Hamazaki, T. (Toyama); Yoshida, S. (Gifu); Kobayashi, T. (Tokyo); Langsjoen, A.M. (Tyler, Tex.)

Original Papers

99 Natakalim Ameliorates Isoproterenol-Induced Chronic Heart Failure by Protecting against Endothelial Dysfunction

115 Effects of Polybrominated Diphenyl Ethers on Rat and Human 11β-Hydroxysteroid Dehydrogenase 1 and 2 Activities
Chen, X.; Dong, Y.; Cao, S.; Li, X.; Wang, Z.; Chen, R.; Ge, R.-S. (Wenzhou)

124 Effects of 22 CYP2D6 Genetic Variations Newly Identified in Chinese Population on Olanzapine Metabolism in vitro
Zhou, H.-Y.; Gu, E.-M.; Chen, Q.; Zhan, Y.-Y. (Wenzhou); Wang, S.-H. (Lishui); Liang, B.-Q. (Wenzhou); Dai, D.-P.; Cai, J.-P. (Beijing); Hu, G.-X. (Wenzhou)

171 Regulation of the Pacemaker Activity of Colonic Interstitial Cells of Cajal by Protease-Activated Receptors: Involvement of Hyperpolarization-Activated Cyclic Nucleotide Channels

183 Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro
Wang, Z.; Gong, Y.; Zeng, D.; Chen, L. (Wenzhou); Lin, G. (Taizhou); Huang, C.; Sun, W.; Chen, M.-C.; Hu, G.; Chen, R. (Wenzhou)

190 Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers

Short Communication

111 Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma Analysis
Géhin, M.; Siddharta, P.N.; Dingemanse, J. (Allschwil)
This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamic properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.

Chemotherapy
Founded: 1959
Category: Clinical and Basic Research
Fields of Interest: Infectious Diseases, Oncology
Listed in bibliographic services, including Journal Citation Reports, PubMed/MEDLINE, Biological Abstracts, Embase, Chemical Abstracts
2016: Volume 62
6 issues per volume
Language: English
ISSN 0009–3157
e-ISSN 1421–9794

Impact Factor: 1.288

More information at www.karger.com/che
Submission
The journal publishes articles dealing with all aspects of experimental and clinical pharmacology. Papers dealing with mechanistic aspects at a molecular level are particularly encouraged. They can be full articles as well as short communications of investigative findings. Reviews, comments and perspective notes on timely topics are specifically welcome. Reviews in which a specific field is reviewed through an exhaustive literature survey. An Abstract is required and should be divided into Background, Summary and Key Messages. Review Articles should consist of a maximum of 4,000 words. We consider investigations dealing with biological extracts or with phytopharmaceutical preparations as outside the scope of our journal. Only papers written in English are considered and should be submitted using the online submission website at:

www.karger.com/pha

or sent as e-mail attachment (the preferred word-processing package is MS-Word) to the Editorial Office:

pha@karger.com

Prof. J. Donnerer
S. Karger AG
Editorial Office 'Pharmacology'
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1356
Fax +41 61 306 1434

Names, postal and e-mail addresses of 4 experts in the appropriate area of research should accompany each manuscript. Referees suggested should not be from the same institution or be research collaborators of the author(s).

Conditions
All manuscripts are subject to editorial review. Manuscripts which do not properly consider ethical issues for humans or animals will not be accepted for publication. In the 'Methods' section, it is recommended to mention the approval given by the responsible authorities. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Pharmacology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Arrangement
Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract of Reviews: Shown divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.

Abstract of Original Papers or Short Communications: Each paper needs an abstract of up to 10 lines.

Drug names: Authors are requested to use International non-proprietary names definitely recommended or, if no final recommendation has been made, proposed by the World Health Organisation (WHO). The use of laboratory code numbers is not recommended. Proposed by the World Health Organisation.

Footnotes: Avoid footnotes. Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labeled with its number and the first author’s name. The final resolution for b/w half-tone and color illustrations must be 300 dpi after scaling. Line drawings require 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (for detailed instructions, see http://www.karger.com/pha).

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.
Supplementary Material
Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:
  ‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author’s Choice™ (Gold Open Access) articles, see Author’s Choice™.

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement:
  ‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page Charges
There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 14 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints
Order form and price list is sent with the pdf proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Contents

See the journal website for contents
The discovery of proton pump inhibitors (PPIs) and their development over the years has dramatically changed the management of acid-related diseases. Today, the therapeutic domain of PPIs ranges from relief of symptoms to cure of mucosal lesions in the upper gastrointestinal tract. PPIs are among the most widely sold drugs in the world and are now even available as over-the-counter medication.

This publication presents the experience of the last 25 years during which PPIs have become of enormous value in gastroenterology. The authors provide an update on a variety of subjects, starting with an introduction to the discovery and development of PPIs. This is followed by chapters on pharmacokinetics, pharmacodynamics and pharmacogenetics, gastroesophageal reflux disease, gastroprotection, Helicobacter pylori eradication treatment, peptic ulcer disease, functional dyspepsia, acid suppression in exocrine pancreatic insufficiency, and gastrointestinal and systemic side effects.

Readers who are interested in a current overview of PPIs and their various applications will find this book of great value.

Contents

Preface: Chiba, T.; Malfertheiner, P.; Satoh, H.

Discovery and Development of Proton Pump Inhibitors: Satoh, H.
Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Proton Pump Inhibitors: Furuta, T.; Sugimoto, M.; Shirai, N.
Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Bruley des Varannes, S.
Proton Pump Inhibitors: Key Ingredients in Helicobacter pylori Eradication Treatment, Peptic Ulcer Disease: Sugiyama, T.
Proton Pump Inhibitor Management in Bleeding Peptic Ulcer Disease: Sung, J.
Proton Pump Inhibitors in Functional Dyspepsia: Miwa, H.
Role of Acid Suppression in Exocrine Pancreatic Insufficiency: A Therapeutic Principle: Waldthaler, A.; Schütte, K.; Malfertheiner, P.
Proton Pump Inhibitors and Gastrointestinal Side Effects: Nakamura, S.; Seno, H.; Chiba, T.
Administration of Proton Pump Inhibitors and Risk of Systemic Side Effects: Kinoshita, Y.; Ishihara, S.
Medical Statistics has never been easier!

David E. Matthews
Vernon T. Farewell

Using and Understanding Medical Statistics
5th, revised and extended edition

The fifth revised edition of this highly successful book presents the most extensive enhancement since Using and Understanding Medical Statistics was first published 30 years ago. Without question, the single greatest change has been the inclusion of source code, together with selected output, for the award-winning, open-source, statistical package known as R. This innovation has enabled the authors to de-emphasize formulae and calculations, and let software do all of the ‘heavy lifting’.

This edition also introduces readers to several graphical statistical tools, such as Q-Q plots to check normality, residual plots for multiple regression models, funnel plots to detect publication bias in a meta-analysis and Bland-Altman plots for assessing agreement in clinical measurements. New examples that better serve the expository goals have been added to a half-dozen chapters. In addition, there are new sections describing exact confidence bands for the Kaplan-Meier estimator, as well as negative binomial and zero-inflated Poisson regression models for over-dispersed count data.

The end result is not only an excellent introduction to medical statistics, but also an invaluable reference for every discerning reader of medical research literature.

Contents
Preface to the Fifth Edition
Prefaces to the Previous Editions
• Basic Concepts
• Tests of Significance
• Fisher’s Test for 2 × 2 Contingency Tables
• Approximate Significance Tests for Contingency Tables
• Some Warnings concerning 2 × 2 Tables
• Kaplan-Meier or ‘Actuarial’ Survival Curves
• The Log-Rank or Mantel-Haenszel Test for Comparing Survival Curves
• An Introduction to the Normal Distribution
• Analyzing Normally Distributed Data
• Linear Regression Models for Medical Data
• Binary Logistic Regression
• Regression Models for Count Data
• Proportional Hazards Regression
• The Analysis of Longitudinal Data
• Analysis of Variance
• Data Analysis
• The Question of Sample Size
• The Design of Clinical Trials
• Further Comments regarding Clinical Trials
• Meta-Analysis
• Epidemiological Applications
• Diagnostic Tests
• Agreement and Reliability

References
Subject Index

The easiest way to order: www.karger.com/medical_statistics

Karger – Medical and Scientific Publishers
CH–4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.